CompoAtlas

NICODERM(R) 14 mg Step 2

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut Quelle
3-(1-Methyl-2-pyrrolidinyl)pyridine

Quelle : Nicotine

78 mg

Nicht arzneiliche Inhaltsstoffe

Polyisobutylene, Polyethylene terephthalate, Polyethylene, Ethylene Vinyl Acetate, Poly(ester)-1

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
AdultesNon précisée1 patch1 Tous les jours

In Kanada zugelassene Verwendungen

NICODERM® 14mg Step 2 is a medicine that can help you stop smoking by reducing withdraw symptoms and nicotine cravings. NICODERM® provides a lower level of nicotine to your blood than cigarettes, and allows you to gradually do away with your body's need for nicotine. It works as a temporary aid to help you quit smoking by reducing nicotine withdrawal symptoms such as irritability, frustration, anxiety, difficulty concentrating and restlessness. Without these powerful urges for the cigarettes you "need", getting rid of the "habit" cigarettes becomes much easier. NICODERM® provides 24 hour rate-controlled delivery of nicotine following its application to intact skin. NICODERM®) reduces the withdrawal symptoms associated with smoking cessation and thus increased the success rate of smoking cessation programs. NICODERM® is the only patch that has a rate controlling membrane, to give your body a steady supply of nicotine to help protect you against cravings. Following the first NICODERM® application, the plasma nicotine concentration rises rapidly, plateaus within 2 to 4 hours and then slowly declines until the system is removed; after which it declines more rapidly. Nicotine in the adhesive layer is absorbed into and through the skin, causing the initial rapid rise in plasma concentration. The nicotine from the reservoir is released slowly through the membrane with a constant release rate. The rate of release of nicotine for NICODERM® 14mg/24hr patch is 1.0mg/hr. Following the second daily NICODERM® system application, steady state plasma nicotine concentration is achieved and is on average 30% higher compared with single dose applications. The quit rate for NICODERM® 14mg/day was 54%. The unique feature offers 24-hour protection, even against the early morning cravings many people find the most difficult.

Originaltext auf Englisch.

Combination Nicotine Replacement Therapy - Nicoderm(R) patch + as needed Nicorette(R) gum/lozenge/oral inhaler/oral mist versus mono Nicotine Replacement Therapy is: - Clinically proven to maximize your chances of quitting - A clinically proven approach to increase your chances of quitting for good -If you have a relapse or experience tough/intense cravings or failed with the patch alone, you can use the patch with as needed Nicorette(R) gum/lozenge/oral inhaler/oral mist at the same time to increase your chances of quit success. - Now you can have the combined support of NICODERM(R) patch and NICORETTE(R) as needed (gum/lozenge, oral inhaler/ oral mist) products together, for a successful quit - Tackle cravings: NICODERM(R) (patch) for slow release constant support and NICORETTE(R) ad lib (as needed gum/lozenge, oral inhaler/ oral mist) for an extra quick fix/dose when you really need to fight back the cravings / when something triggers intense cravings. - Combination therapy is 30%/1.3x more effective than using one Nicotine Replacement Therapy product alone - Use NICODERM® patch + NICORETTE® (gum/lozenge/inhaler/oral mist) together to increase your chance of quitting

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Keep out of reach of children. DO NOT USE IF YOU: are under 18 years of age; are an occasional or non-smoker; are pregnant or nursing; have generalized skin disorders (e.g., eczema, rash); are allergic to nicotineor any of the non-medicinal ingredients. Check with your doctor or pharmacist before using NICODERM®patches if you have had any of the following: a heart attack (myocardial infarction), irregular heart beat (arrhythmia), high blood pressure, a history of epilepsy or seizures, thyroid problems, stomach problems, kidney or liver disease, treatment of circulation disorders of the brain, are taking any prescription drugs, rashes from adhesive tape or bandages, inflammation of the esophagus, heart pain (angina), stroke, heart disease, blood circulation problems, stomach ulcers, diabetes requiring insulin, allergies to drugs, skin diseases, a tumor of the adrenal gland (phaeochromocytoma). If you have diabetes, you may need to monitoryour blood sugar levels more closely than normal when you stop smoking and start using this product. Signs of an overdose include bad headaches, dizziness, nausea, abdominal pain, drooling, vomiting, diarrhea, coldsweat, blurred vision, difficulty with hearing, mental confusion, weakness and fainting, rapid heartbeat and difficulty breathing. At high doses, these symptoms may be followed by low blood pressure, weak and irregular pulse, breathing difficulties, extreme exhaustion, circulatory collapse and general convulsions.

Originaltext auf Englisch.

Produktdaten

Inhaber
Kenvue Canada Inc.
NPN oder DIN-HM
80044503
Status
Aktive Lizenz
Lizenzdatum
30. August 2013
Überarbeitungsdatum
29. Juli 2024
Form
Timbre transdermique
Verabreichungsweg
Transdermique
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80044503

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2024. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile